SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-002891
Filing Date
2023-01-26
Accepted
2023-01-26 16:12:52
Documents
14
Period of Report
2023-01-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10047048_8k.htm   iXBRL 8-K 33093
2 EXHIBIT 99.1 brhc10047048_ex99-1.htm EX-99.1 12408
6 image0.jpg GRAPHIC 101414
  Complete submission text file 0001140361-23-002891.txt   332627

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA knte-20230125.xsd EX-101.SCH 3863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE knte-20230125_lab.xml EX-101.LAB 23291
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knte-20230125_pre.xml EX-101.PRE 16551
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10047048_8k_htm.xml XML 4425
Mailing Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130
Business Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130 8582994699
Kinnate Biopharma Inc. (Filer) CIK: 0001797768 (see all company filings)

IRS No.: 824566526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39743 | Film No.: 23557825
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences